ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism

David H. Peng, Samrat T. Kundu, Jared J. Fradette, Lixia Diao, Pan Tong, Lauren A. Byers, Jing Wang, Jaime Rodriguez Canales, Pamela A. Villalobos, Barbara Mino, Yanan Yang, Rosalba Minelli, Michael D. Peoples, Christopher A. Bristow, Timothy P. Heffernan, Alessandro Carugo, Ignacio I. Wistuba, Don L. Gibbons

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors have failed to show clinical benefit in Kirsten rat sarcoma (KRAS) mutant lung cancer due to various resistance mechanisms. To identify differential therapeutic sensitivities between epithelial and mesenchymal lung tumors, we performed in vivo small hairpin RNA screens, proteomic profiling, and analysis of patient tumor datasets, which revealed an inverse correlation between mitogen-activated protein kinase (MAPK) signaling dependency and a zinc finger E-box binding homeobox 1 (ZEB1)-regulated epithelial-to-mesenchymal transition. Mechanistic studies determined that MAPK signaling dependency in epithelial lung cancer cells is due to the scaffold protein interleukin-17 receptor D (IL17RD), which is directly repressed by ZEB1. Lung tumors in multiple Kras mutant murine models with increased ZEB1 displayed low IL17RD expression, accompanied by MAPK-independent tumor growth and therapeutic resistance to MEK inhibition. Suppression of ZEB1 function with miR-200 expression or the histone deacetylase inhibitor mocetinostat sensitized resistant cancer cells to MEK inhibition and markedly reduced in vivo tumor growth, showing a promising combinatorial treatment strategy for KRAS mutant cancers. In human lung tumor samples, high ZEB1 and low IL17RD expression correlated with low MAPK signaling, presenting potential markers that predict patient response to MEK inhibitors.

Original languageEnglish (US)
Article numbereaaq1238
JournalScience translational medicine
Issue number483
StatePublished - 2019

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism'. Together they form a unique fingerprint.

Cite this